Construction of novel human monoclonal antibodies neutralizingPorphyromonas gingivalishemagglutination activity using transgenic mice expressing human Ig loci

Porphyromonas gingivalishas been implicated as an important pathogen in the development of adult periodontitis, and its colonization of subgingival sites is critical in the pathogenic process. One potential virulence factor, hemagglutinin, may mediate bacteria attachment onto and penetration into ho...

Full description

Saved in:
Bibliographic Details
Published in:Vaccine 2005-05, Vol.23 (29), p.3850
Main Authors: Shibata, Yasuko, Hosogi, Yumiko, Hayakawa, Mitsuo, Hori, Nobuaki, Kamada, Masafumi, Abiko, Yoshimitsu
Format: Article
Language:English
Subjects:
Cloning
Disease
Fertility
Hydroxyapatite
Immune system
Immunization
Immunotherapy
Molecular weight
Periodontal diseases
Proteins
Technological change
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Porphyromonas gingivalishas been implicated as an important pathogen in the development of adult periodontitis, and its colonization of subgingival sites is critical in the pathogenic process. One potential virulence factor, hemagglutinin, may mediate bacteria attachment onto and penetration into host cells, as well as agglutinate and lyses erythrocytes to intake heme, an absolute requirement for growth. Toward the development of passive immunotherapy, the construction of a human type monoclonal antibody, which is capable of inhibiting the hemagglutinating ability, will be significant and important. The human mAbs, both exhibiting a high degree of specificity and affinity against the recombinant 130kDa hemagglutinin domain protein have been prepared using XenoMouse technology. The constructed Xeno-mAbs, IgG2 subclass, significantly inhibited hemagglutination ofP. gingivalisand its vesicles. The newly constructed Xeno-mAbs may prove to be useful for the development of passive immunization against periodontal diseases caused byP. gingivalisinfection, pending the results of fertility study in disease mode.
ISSN:0264-410X
1873-2518
DOI:10.1016/j.vaccine.2005.01.159